Spinal Cord Injury Pipeline Review, H2 2013 report provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Spinal Cord Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spinal Cord Injury. Spinal Cord Injury Pipeline Review, Half Year is built using data and information sourced from publisher proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher team. For more information visit: Spinal Cord Injury - Pipeline Review, H2 2013
Scope
- A snapshot of the global therapeutic scenario for Spinal Cord Injury.
- A review of the Spinal Cord Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Spinal Cord Injury pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Spanning over 176 pages 40 tables and 14 figures, “Spinal Cord Injury - Pipeline Review, H2 2013” report identify and understand important and diverse types of therapeutics under development for Spinal Cord Injury. Browse more: Healthcare Market Research Reports Analysis
No comments:
Post a Comment
Note: only a member of this blog may post a comment.